Delving into the Latest Updates on [11C]CPPC with Synapse

Overview

Basic Info

Drug Type

Chemical drugs, Diagnostic radiopharmaceuticals

Synonyms-

Target

CSF-1R

Mechanism

CSF-1R modulators(Colony stimulating factor 1 receptor modulators), PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases+ [2]

Active Indication

Amyotrophic Lateral SclerosisPost Acute COVID 19 Syndrome

Inactive Indication-

Originator Organization

The Johns Hopkins University

Active Organization

Defense Language Institute Foreign Language Center

The Johns Hopkins University

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

1. Establish the safety and tolerability of the 5-cyano-N-(4-(4-[11C]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide ([11C]CPPC) PET radioligand in ALS patients and controls
2. Examine whether [11C]CPPC PET uptake is elevated in brains of ALS patients and whether there is a correlation with clinical phenotype.
3. Correlate [11C]CPPC PET imaging with other ALS outcome measures and biofluid biomarkers
4. Examine longitudinal changes in [11C]CPPC PET imaging during disease course.

Start Date01 Jan 2025

Sponsor / Collaborator

The Johns Hopkins University

[+1]

NCT06223971 / RecruitingEarly Phase 1IIT

A Phase l Study to Assess the Safety and Tolerability of PET Imaging With [11 C]CPPC [5-cyano-N-( 4-( 4-[l l CJ me1hylpiperazin-l-yl)-2-(Piperidin-l-yl)Phenyl)Furan-2-carboxamide] Radioligand and Magnetic Resonance (MR) Imaging in Patients With Long COVID.

The goal of this study is to evaluate the safety of using the [5-cyano-N-(4-(4-[11C]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide] ([11C]CPPC) radiotracer in positron emission tomography (PET) imaging of people with history of COVID-19 infection, with and without symptoms. The investigators are also interested to see whether use of this radiotracer reveals imaging differences between patients with history of COVID-19 infection and still exhibiting symptoms or healthy patients with history of COVID-19 infection but exhibiting no current symptoms.

Start Date06 Aug 2024

Sponsor / Collaborator

The Johns Hopkins University

[+1]

NCT04749433 / TerminatedPhase 1IIT

A Phase 1 Study to Assess the Safety and Tolerability of PET Imaging With [11C]CPPC [5-cyano-N-(4-(4-[11C]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide] Radioligand in Patients With Amyotrophic Lateral Sclerosis

The goal of this study is to evaluate the safety of using the [5-cyano-N-(4-(4-[11C]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide] ([11C]CPPC) radiotracer in positron emission tomography (PET) imaging of people with amyotrophic lateral sclerosis (ALS). The investigators are also interested to see whether use of this radiotracer reveals imaging differences between patients with ALS and healthy patients.

Start Date01 Sep 2021

Sponsor / Collaborator

The Johns Hopkins University

[+1]

100 Clinical Results associated with [11C]CPPC

Login to view more data

100 Translational Medicine associated with [11C]CPPC

Login to view more data

100 Patents (Medical) associated with [11C]CPPC

Login to view more data

1

Literatures (Medical) associated with [11C]CPPC

American Journal of Nuclear Medicine and Molecular Imaging

Automated radiosynthesis of [11C]CPPC for in-human PET imaging applications

Article

Author: Woodcock, Eric A ; Roy, Pritam ; Guo, Yan ; Jiang, Huailei ; Muzik, Otto

The macrophage colony-stimulating factor 1 receptor (CSF1R) is almost exclusively expressed in microglia, representing a biomarker target for imaging of microglia availability. [¹¹C]CPPC has specific binding affinity to CSF1R and suitable kinetic properties for in vivo PET imaging of microglia. However, previous studies reported a low radiochemical yield, motivating additional research to optimize [¹¹C]CPPC radiochemistry. In this work, we report an automated radiosynthesis of [¹¹C]CPPC on a Synthra MeIPlus module with improved radiochemical yield. The final [¹¹C]CPPC product was obtained with excellent chemical/radiochemical purities and molecular activity, facilitating high-quality in-human PET imaging applications.

100 Deals associated with [11C]CPPC

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amyotrophic Lateral Sclerosis	Phase 2	-	Defense Language Institute Foreign Language Center	01 Jan 2025
Amyotrophic Lateral Sclerosis	Phase 2	-	The Johns Hopkins University	01 Jan 2025
Post Acute COVID 19 Syndrome	Phase 1	US	The Johns Hopkins University	06 Aug 2024